What happens when you take diltiazem with grapefruit?
Diltiazem is a non-dihydropyridine calcium channel blocker used for high blood pressure, angina, and rate control in atrial fibrillation. It is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver and the lining of the small intestine. Grapefruit and grapefruit juice contain furanocoumarins, especially bergamottin and 6,7-dihydroxybergamottin, that bind to intestinal CYP3A4 and inactivate it for roughly 24 to 72 hours. With less first-pass metabolism in the gut, more diltiazem reaches the bloodstream.
In a controlled study published in the European Journal of Clinical Pharmacology, healthy volunteers who took diltiazem with 300 mL of regular-strength grapefruit juice had a statistically significant 20 percent average increase in diltiazem area under the curve (AUC), with peak concentrations rising by about 22 percent. Importantly, the increase varied widely between individuals: some saw very little change while others had much larger spikes. That variability is the main reason this interaction matters clinically even though the average effect is modest.
Why is this important?
Diltiazem slows the heart rate, weakens cardiac contractility, and dilates arteries. When blood levels rise unpredictably, the result can be excessive bradycardia (slow heart rate), low blood pressure, dizziness, fatigue, or in rare cases AV block. People who are most at risk are those who are already on the upper end of their diltiazem dose, those taking other heart-rate-lowering drugs such as beta blockers, digoxin, or amiodarone, and older adults with reduced baseline kidney or liver function.
Diltiazem has a moderate first-pass effect, so it sits in the middle of the grapefruit-sensitivity spectrum: not as dramatic as felodipine or simvastatin (where AUC can double or triple), but more clinically meaningful than amlodipine (where no signal is seen at normal intakes). The interaction lasts longer than people expect because grapefruit irreversibly inactivates the enzyme — spacing the juice and the pill by a few hours does not eliminate the effect. Enzymes take days to regenerate.
What should you do?
The safest practice is to avoid grapefruit, grapefruit juice, Seville oranges, pomelos, and tangelos while taking diltiazem. If you have been a regular grapefruit consumer and have stable blood pressure and pulse, your numbers already reflect that pattern, but adding new grapefruit while your dose is being adjusted is a bad idea. During any dose titration, switch to non-interacting citrus like sweet oranges, mandarins, lemons, or limes.
If you cannot or do not want to give up grapefruit, do the following: tell your prescriber so they can watch for exaggerated effects, check your home blood pressure and pulse regularly, and report symptoms like dizziness on standing, fainting, slow heart rate (below 50 bpm), unusual fatigue, or worsening ankle swelling.
Which specific products are affected?
This applies to all oral diltiazem products including immediate-release tablets and the many extended-release brands and generics such as Cardizem CD, Cardizem LA, Tiazac, Dilacor XR, Cartia XT, Taztia XT, and Matzim LA. Intravenous diltiazem given in hospital settings bypasses the gut, so the grapefruit effect on first-pass metabolism is irrelevant for the IV form.
Whole grapefruit, fresh grapefruit juice, frozen concentrate, grapefruit-flavored beverages that contain real juice, Seville oranges (often used in marmalade), pomelos, and tangelos all contain the relevant furanocoumarins. Standard sweet oranges (navel, Valencia), blood oranges, mandarins, clementines, lemons, and limes do not.
The bottom line
Diltiazem and grapefruit is a moderate interaction with high person-to-person variability. The most defensible approach is to avoid grapefruit while taking diltiazem, particularly during dose adjustments or if you take other heart-rate-lowering drugs. The interaction does not depend on timing because grapefruit's effect on intestinal CYP3A4 lasts for days, so simply spacing them apart does not prevent the increase in diltiazem exposure.